

(2) *Related substances.* Proceed as directed in paragraph (b)(1) of this section for rifabutin content using the sample prepared as described in paragraph (b)(1)(i) of this section and calculating the amounts of related substances as follows.

(i) *Calculations.* Calculate the percentage of related substances as follows:

$$\text{Percent individual HPLC - related substance} = \frac{A_i \times 100}{A_t}$$

$$\text{Percent total HPLC - related substances} = \frac{A \times 100}{A_t}$$

where:

$A_i$  = Area of the individual related substance peak;

$A$  = The sum of areas of all peaks minus the area due to the rifabutin peak and solvent front peak; and

$A_t$  = The sum of areas of all peaks in the chromatogram excluding the solvent peak.

(ii) [Reserved]

(3) *Dissolution test.* Proceed as directed in §436.215 of this chapter. The quantity (Q) (the amount of rifabutin activity dissolved) is 75 percent within 45 minutes.

(4) *Identity.* (i) The retention time of the rifabutin response in the HPLC procedure described in paragraph (b)(1) of this section as applied to the sample solution compares qualitatively to that of the rifabutin reference standard.

(ii) The identity of rifabutin capsules is also confirmed by the spectrophotometric identity test described in §436.370 of this chapter.

[59 FR 40808, Aug. 10, 1994]

### Subpart C—Injectable Dosage Forms

#### § 455.204 Aztreonam injectable dosage forms.

##### § 455.204a Aztreonam for injection.

(a) *Requirements for certification—(1) Standards of identity, strength, quality, and purity.* Aztreonam for injection is a dry mixture of aztreonam and arginine. Its potency is satisfactory if each mil-

ligram of aztreonam for injection contains not less than 900 micrograms and not more than 1,050 micrograms of aztreonam when corrected for arginine content and moisture content. Its aztreonam immediate container fill (content) is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of aztreonam that it is represented to contain. It is sterile. It is nonpyrogenic. Its moisture content is not more than 2.0 percent. Its pH in an aqueous solution containing 100 milligrams of aztreonam per milliliter is not less than 4.5 and not more than 7.5. The aztreonam used conforms to the standards prescribed by §455.4a(a)(1), except if the aztreonam for injection is manufactured by lyophilization, in which case the aztreonam need not be sterile.

(2) *Labeling.* It shall be labeled in accordance with the requirements of §432.5 of this chapter.

(3) *Requests for certification; samples.* In addition to complying with the requirements of §431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The aztreonam used in making the batch for potency, sterility, pyrogens, moisture, residue on ignition, heavy metals, and identity. If the aztreonam for injection is made by lyophilization, the aztreonam need not be tested for sterility.

(b) The batch for aztreonam potency, aztreonam content, sterility, pyrogens, moisture, and pH.

(ii) Samples, if required by the Director, Center for Drug Evaluation and Research:

(a) The aztreonam used in making the batch: 10 packages, each containing approximately 500 milligrams.

(b) The batch:

(1) For all tests except sterility: A minimum of 10 immediate containers.

(2) For sterility testing: 20 immediate containers, collected at regular intervals throughout each filling operation.

(b) *Tests and methods of assay—(1) Potency and content.* Determine both micrograms of aztreonam per milligram of sample and milligrams of aztreonam per container. Proceed as